The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended that Givlaari (givosiran) be granted marketing authorization in the European Union.
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended that Givlaari (givosiran) be granted marketing authorization in the European Union, according to a Jan. 31, 2020 press release.
Givlaari is a treatment for acute hepatic porphyria (AHP), which is a rare genetic condition and potentially life-threatening. There are no currently approved treatments that directly ameliorate or prevent chronic symptoms associated with AHP.
CHMP’s recommendation has been based on the results of a Phase III clinical study, demonstrating the benefits and safety of the treatment in 94 patients with AHP who had experienced at least two attacks within the past six months. As Givlaari addresses an unmet medical need, it has been afforded accelerated assessment by the regulatory body.
The recommendation will be submitted to the European Commission for consideration and, if approved, will be authorized for marketing across the EU for adult patients and adolescents aged 12 years and older with AHP. Authorization application for Givlaari was submitted by Alnylam Netherlands.
Source: EMA
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
2 Commerce Drive
Cranbury, NJ 08512